Stan Watowich
Seminars
Monday 29th September 2025
9:15 am Sustainable Treatments to Reverse MASH & Obesity-Linked Comorbidities
- Quelling hepatic injury through strategic inflammatory modulation to dampen the damaging inflammatory cascade within the liver to benefit the long-term trajectory of the disease
- Understanding the biology of targeting chemokine receptors (e.g., CCR2/CCR5 inhibition) to limit the recruitment of inflammatory cells to the liver to introduce a new method of treating MASH
- Investigating the potential of inhibiting apoptosis pathways (e.g., ASK1 inhibition) to preserve hepatocytes to reduce liver damage driven by inflammation
Monday 29th September 2025
3.15 pm Panel Discussion: Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes
- Integrating the design of therapies involving novel mechanisms with new, predictive biomarkers to provide a more precise and efficient approach to drug discovery and development for earlier identification of responders and non-responders
- Leveraging cutting-edge understanding of MASH pathogenesis to design innovative therapies to target the root causes of the disease for more effective treatments that can holistically improve patient outcomes
- Developing and validating novel predictive biomarkers alongside new therapeutic candidates for early and accurate identification of patient response for more streamlined clinical trials and impactful MASH therapies
